Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Twist Bioscience is lead sponsor; 0 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13G/A2026-09-08SCHEDULE 13G/A
- SCHEDULE 13G/A2026-09-08SCHEDULE 13G/A
- 8-K2026-08-19Current report (material event)
- 424B72026-08-19424B7
- 8-K2026-08-19Current report (material event)
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- SCHEDULE 13G2026-08-14SCHEDULE 13G
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
- SCHEDULE 13G/A2026-08-11SCHEDULE 13G/A
- SCHEDULE 13G2026-08-06SCHEDULE 13G
- 8-K2026-08-05Current report (material event)
- 424B52026-08-05Prospectus (offering)
- 424B52026-08-04Prospectus (offering)
- 10-Q2026-08-03Quarterly report
- 8-K2026-08-03Current report (material event)
- S-3ASR2026-06-18S-3ASR
- SCHEDULE 13G/A2026-05-07SCHEDULE 13G/A
- 10-Q2026-05-04Quarterly report
- 8-K2026-05-04Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- SCHEDULE 13G/A2026-04-30SCHEDULE 13G/A
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- SCHEDULE 13G/A2026-03-06SCHEDULE 13G/A
- UPLOAD2026-03-05UPLOAD
- CORRESP2026-02-26CORRESP
- 10-Q/A2026-02-26Quarterly report (amended)
- UPLOAD2026-02-19UPLOAD
- SCHEDULE 13G/A2026-02-17SCHEDULE 13G/A
- 424B72026-02-17424B7
- 8-K2026-02-17Current report (material event)
- SCHEDULE 13G/A2026-02-09SCHEDULE 13G/A
- 8-K2026-02-06Current report (material event)
- SCHEDULE 13G/A2026-02-03SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-03SCHEDULE 13G/A
- 10-Q2026-02-02Quarterly report
- 8-K2026-02-02Current report (material event)
- 8-K2026-01-12Current report (material event)
- ARS2026-01-06Annual report to holders
- DEF 14A2026-01-06Proxy statement
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.